News | SPECT-CT | August 24, 2016

Molecular Dynamics' CZT-based Digital SPECT/CT Trial Shows Promising Results

Digital detector-based SPECT/CT prototype displays improved sharpness and contrast compared to analog SPECT

Valiance X12, SPECT/CT, CZT detectors, clinical trial

Tc99m MDP SPECT bone study images of a 35 year old male with right ankle pain. Top: Valiance X12. Bottom: Analog SPECT. Image courtesy of Molecular Dynamics.

August 24, 2016 — Molecular Dynamics has successfully completed the first phase of a clinical trial to evaluate the Valiance X12 whole-body cadmium zinc telluride (CZT)-based digital SPECT/CT prototype with promising results. The study, conducted at the Chaim Sheba Medical Center in Israel, was designed to assess the image quality and diagnostic performance of the Valiance X12 and demonstrated improved image resolution and contrast.

The Valiance X12 was used to acquire digital SPECT (single photon emission computed tomography) scans from 25 patients, who had previously undergone analog SPECT scans, at the Department of Nuclear Medicine under the supervision of Ronen Goldkorn, M.D., and Elinor Goshen, M.D.  

The Valiance X12 digital studies were reviewed by experienced readers and were compared to the analog studies. Images were graded on a scale of 1 (poor) to 4 (very good) for sharpness and contrast. The mean grades for the Valiance X12 digital SPECT images exceeded those of analog SPECT images for sharpness (3.8 vs 3.1) and contrast (3.9 vs 3.3). Furthermore, focused digital SPECT on a specific region of interest was shown to further increase both the sharpness and contrast of the Valiance X12 images.  

"These findings are promising for CZT-based digital SPECT," said Goshen.  "Further research will assess other general nuclear medicine applications, as well as the contribution of focused imaging, a unique capability of the Valiance X12."

The unique architecture of the Valiance X12 includes CZT-based detectors with independent radial swivel motion, gantry rotation and adaptive image acquisition, which focus the detectors on specific regions, providing multiple angular views and enhanced images of a target.

Goshen will present these results along with additional findings at the European Association of Nuclear Medicine Annual Congress, Oct. 15-19 in Barcelona, Spain.

For more information: www.molecular-d.com

Related Content

MEDraysintell Projects Increasing Mergers and Acquisitions in Nuclear Medicine
News | Nuclear Imaging | November 07, 2018
With the recent announcement by Novartis to acquire Endocyte , interest from the conventional pharmaceutical industry...
Proton Therapy for Pediatric Brain Tumors Has Favorable Cognitive Outcomes
News | Proton Therapy | November 06, 2018
Proton therapy treatment for pediatric brain tumor patients is associated with better neurocognitive outcomes compared...
A PET/CT head and neck cancer scan.

A PET/CT head and neck cancer scan.

Feature | Nuclear Imaging | November 05, 2018 | By Sabyasachi Ghosh
“Experimental validation implemented in real-life situations and not theoretical claims exaggerating small advantages
150-Year-Old Drug Might Improve Radiation Therapy for Cancer
News | Radiation Therapy | November 02, 2018
November 2, 2018 — A drug first identified 150 years ago and used as a smooth-muscle relaxant might make tumors more
SBRT Considered Safe Treatment Option for Patients With Multiple Metastases
News | Stereotactic Body Radiation Therapy (SBRT) | November 01, 2018
The NRG Oncology clinical trial BR001 tested the hypothesis that stereotactic body radiotherapy (SBRT) could be used...
Hypofractionated Radiation Provides Same Prostate Cancer Outcomes as Conventional Radiation
News | Intensity Modulated Radiation Therapy (IMRT) | October 31, 2018
An analysis led by researchers at Philadelphia’s Fox Chase Cancer Center found treating localized prostate cancer with...
Prostate Brachytherapy Shows Low Incidence of Short-Term Complications
News | Brachytherapy Systems | October 31, 2018
A new analysis of nearly 600 men receiving brachytherapy for prostate cancer shows overall procedure-related...
Biomarker blood test accurately confirms remission in non-smoker with HPV-associated oral cancer. ASTRO 2018 #ASTRO2018 #ASTRO #ASTRO18

Biomarker blood test accurately confirms remission in non-smoker with HPV-associated oral cancer.

News | Radiation Oncology | October 30, 2018
October 30, 2018 — A highly sensitive blood test that detects minute traces of cancer-specific DNA has been shown to